Leadership Team

Joe Massaro, Chief Financial Officer for inVentiv Health, has more than 18 years of experience as a finance executive in complex service, distribution, and manufacturing organizations.

Before joining inVentiv Health, Mr. Massaro was a Managing Director at Liberty Lane Partners, LLC, a private investment firm that applies its unique operational and financial expertise to its portfolio companies to achieve above-market returns.

Prior to joining Liberty Lane Partners, Mr. Massaro served in several senior financial and operational roles
at Thermo Fisher Scientific, including Senior Vice President Global Business Services and Vice President Corporate Finance and Accounting. In addition, Mr. Massaro served as Vice President Strategic Planning
at Fisher BioPharma Services, a division of Thermo Fisher Scientific focused on providing outsourced clinical trial management and logistics to the pharmaceutical and biotechnology industries. Prior to Thermo Fisher, Mr. Massaro served in various capacities in the advisory business services practice at PricewaterhouseCoopers
in Boston.

Mr. Massaro holds a bachelor’s degree from Bentley University. He holds a master’s degree in accounting
and an MBA from Northeastern University.

Robert Chandler is President, inVentiv Health Communications and Senior Vice President, Marketing and Communications, inVentiv Health. Mr. Chandler is also co-founder of Chandler Chicco Companies, part of inVentiv Health since 2007.

Mr. Chandler is one of the healthcare industry’s most experienced communications consultants. In 1995, he and business partner, Gianfranco Chicco, founded Chandler Chicco Agency (CCA), which quickly grew to become Chandler Chicco Companies (CCC), providing best-in-class capabilities spanning public relations, digital and social media, medical education, public affairs, branding and design, corporate identity, financial and investor relations, and research and measurement. CCC has won some of the most prestigious awards in the industry, including The Holmes Report Global Healthcare Agency of the Year (2012), Healthcare Agency of the Decade (2000-2010), Healthcare Agency of the Year (2002-2009), Specialist Agency of the Year (2006-2007), and Creative Agency of the Year (2006); and PRWeek’s Number 1 European Healthcare Consultancy (2008-2011), and Agency of the Year and Midsize Agency of the Year ( 2007). With revenue exceeding $80 million, CCC has offices in New York, London, Los Angeles, Washington, Philadelphia, Frankfurt, Paris and Shanghai, as well as a global affiliate network spanning 45 markets worldwide.

Previously, Mr. Chandler was Executive Vice-President and Co-Managing Director of Burson-Marsteller’s healthcare practice and president of the agency’s The Biotech Group. He also served as VP/Assistant Administrator for Marketing and Public Affairs at Methodist Hospital in Brooklyn.

In 2007, Mr. Chandler was awarded the Ohio University Alumni Medal of Merit and in 2010, he received the SABRE Lifetime Achievement Award from The Holmes Report.

Mr. Chandler has a BS in Journalism from Bowling Green State University; an MS in Journalism from Ohio University; and an MBA in Health Services Administration from Wagner College.

Mr. Chandler sits on the Board of Directors of The Ranney School in New Jersey.

As inVentiv Health’s Chief Human Resources Officer, Duncan Harwood is responsible for providing strategic HR leadership, which includes designing and implementing effective organizational strategies for the company to attract and retain the best talent. He also drives HR strategy for inVentiv’s three business segments, Clinical, Commercial and Consulting.

Mr. Harwood joined inVentiv from PriceWaterhouseCoopers (PwC), where he served as Principal and founding Partner of the company’s HR consulting practice, leading it to become one of the top three HR transformation advisory practices in the world. In his 10 years at PwC, Mr. Harwood worked with over 100 large companies across a variety of industries to help their HR organizations become more strategically focused, improve their impact on business outcomes and increase their efficiency. Prior to PwC, he was a Worldwide Partner in the Human Capital Practice at Andersen and a Principal at Mercer HR Consulting.

Mr. Harwood holds a bachelor’s of science degree from the University of Kansas and the SPHR certification from the Society for Human Resource Management.

Ray Hill leads the inVentiv Health Clinical business segment and brings extensive experience in successfully growing pharmaceutical services businesses and leading productive teams to the organization. He has lived and worked in Asia, Europe, and the United States.

Prior to joining inVentiv Health in 2012, Mr. Hill was CEO at Pharmaceutical Product Development, Inc., where he successfully oversaw the process of taking the company private. Before that, he was President at IMS Consulting Group, where he led an aggressive strategy of organic growth and acquisitions – building the business to $500M in 2010, and then helping to take the company private. Prior to IMS, Mr. Hill held a series of other positions in pharmaceutical consulting. He earned a bachelor’s degree from Cornell University and a master’s degree from Duke University.

As Executive Vice President, Steve Roycroft oversees inVentiv Health’s Commercial and Consulting business segments. He focuses on driving operational excellence across the two segments, identifying unmet client needs and working with business leaders to develop new collaborative solutions. In addition, Mr. Roycroft leads inVentiv’s Global Strategic Corporate Accounts team, which provides coordinated account management for the company’s top clients, and serves on the board of Campbell Alliance, an inVentiv Health company and leader in management consulting to biopharmaceutical and medical technology companies.

Mr. Roycroft brings more than 20 years of business operations, general management and entrepreneurial experience to inVentiv. Most recently, he served as Executive Vice President and Global Managing Director at Thomson Reuters Corporation. In this role, Mr. Roycroft was responsible for Thomson Reuters’ Corporate Services business, where he led the development of new products, drove global strategies to upgrade talent and significantly improved the division’s financial performance.

Earlier in his career, Mr. Roycroft served as Vice President of Sales and Commercial Operations at CCBN, a web-based communication solutions company later acquired by Thomson Financial. During his tenure at CCBN, Roycroft helped build the company’s client base to include more than 3,000 corporations and 20,000 institutional investors.

Mr. Roycroft has a bachelor’s degree in Business Administration from Stonehill College.

Mark Dmytruk is President of inVentiv Health Patient Outcomes, a sub-segment of the inVentiv Health Commercial segment. He is based at inVentiv Health’s headquarters in Burlington, Massachusetts.

inVentiv Health Patient Outcomes provides a broad range of services relating to patient adherence, patient reimbursement and financial assistance, disease management and cost containment, accountable care solutions, and risk management consulting. inVentiv companies operating under this sub-segment include Adheris, inVentiv Medical Management, inVentiv Patient Access Solutions and ParagonRx.

Mr. Dmytruk has extensive experience in the healthcare, life sciences, and diagnostics industries, including emerging and international market development. He joined inVentiv Health from Athena Diagnostics, a leader in molecular diagnostics and personalized medicine, where he was Vice President of Finance and a member of the executive leadership team. Prior to Athena, Mr. Dmytruk was Vice President of Corporate Development at Thermo Fisher Scientific, where he led Thermo Fisher’s merger and acquisition activity worldwide and contributed to revenue growth from $3B to $10B over eight years. Other affiliations include working with Ernst & Young in both Canada and Eastern Europe.

Mr. Dmytruk holds a bachelor’s degree from the University of Alberta in Edmonton, Canada, and an MBA from the Sloan School of Management at MIT.

Rick Finnegan is Executive Vice President of International Business in the company’s Commercial segment.
In this role, he drives the strategy for expanding the Commercial business internationally and oversees planning for the company’s growth in markets outside the United States.

Since 2009, inVentiv Health’s global footprint in clinical, commercial, and consulting services has grown significantly. This includes the launch of inVentiv Health Japan in 2009, a business that is now among the largest contract sales organizations (CSO) in Japan.

Mr. Finnegan joined inVentiv Health with more than 25 years of experience in the pharmaceutical industry, serving in executive roles for a variety of companies ranging from large corporations to start-up ventures.
He served most recently at Glenmark Therapeutics, a specialty pharmaceutical company based in Mumbai, India, where he led its central/eastern European division as Senior Vice President of Specialty Pharmaceuticals based in Prague, Czech Republic. Prior to Glenmark, Mr. Finnegan spent more than a decade at Merck in marketing leadership positions of increasing responsibility, including Senior Director Worldwide of New Products/Anti-Infectives in the Worldwide Human Health Marketing Division.

Mr. Finnegan holds a bachelor’s degree in business administration and life sciences from the University
of New Hampshire, and he holds a master’s degree from the Sloan School of Management at MIT.

Kelly Gratz’s most recent responsibilities include serving as President of inVentiv Health Selling Accelerators, championing the integration across the Commercial Division. She has a unique blend of experience, holding senior positions within inVentiv’s communications and commercial divisions, and leading collaborative initiatives across all segments of the business.

Kelly has been at the forefront of ReAgent™, a proprietary methodology to strategically allocate and optimize commercialization resources. Kelly also brings direct experience in driving topline growth for brands in an outsourced, risk sharing model as well as operational experience.

Since joining inVentiv Health in 2000, Kelly has been directly involved in driving multi-channel success for a number of pharmaceutical clients, including Ortho-McNeil Neurologics, Merck, Ethicon, TAP, BMS, Eli Lilly and Company, Genentech, AstraZeneca, GlaxoSmithKline, Ross Products, Takeda, and UCB Pharma.

Prior to inVentiv Health, Kelly served in an executive management position for Symix Systems, a marketer and developer of e-business software. Previous to Symix, Kelly spent over 10 years with Ernst & Young LLP in their management consulting group, working with Fortune 500 companies to improve processes and increase overall efficiencies throughout each organization.

Mike Ivers, Chief Operating Officer of PharmaNet/i3, actively participates in and leads day-to-day operations to enhance PharmaNet/i3's productivity and client service.

In his previous role as Executive Vice President of inVentiv Health, Mr. Ivers played a lead role in driving the integration and growth of the company’s expanding Clinical segment. He also helped support the formulation and implementation of inVentiv’s overall global growth strategy.

Mr. Ivers has more than 30 years of experience in the pharmaceutical and drug development industry. He served as Global President of Fisher BioPharma Services and later as Division President of ThermoFisher, where he successfully built the division into a $700 million industry leader. Previously, Mr. Ivers served at Covance as Vice President and General Manager overseeing the global clinical supplies business. He also held corporate roles at the company in the U.S. and Europe.

Prior to Covance, Mr. Ivers worked for 18 years at SmithKline Beecham in a variety of management roles including finance, marketing, product development, strategic planning and operational management.

Mr. Ivers originates from the U.K., where he initially started his career in finance, working in both private practice and industry after qualifying as a Chartered Accountant.

Mr. Mignon successfully leads inVentiv Health Selling Solutions, which encompasses all of the companies
that relate to sales teams and sales support services.

In his current role, Mr. Mignon is responsible for the development and execution of comprehensive, customized selling solutions that support many of the major pharmaceutical firms, as well as effectively delivering cross-selling and integrated solutions to clients that include services across the broader inVentiv Health organization.

Mr. Mignon joined inVentiv Health in 2002 when he assumed the leadership role for the sales organization. Since that time, he has expanded the active client roster and significantly diversified their service portfolio.
As a consultative business partner, Mr. Mignon has strengthened and stabilized client relationships by providing innovative products and services to meet the challenges of the dynamic pharmaceutical marketplace.

Mr. Mignon’s depth of experience is built on a successful 14-year career with Johnson & Johnson. During his tenure, he was recognized for many significant accomplishments while holding various leadership roles within the Johnson & Johnson family of companies, including National Sales Director, Sales Training Director, Product Director, and Division Manager.

Mr. Mignon is a graduate of Lafayette College, where he holds a bachelor’s degree in history. He is a member of the editorial board for Product Management Today and serves on the Board of Directors for the Cancer Institute of New Jersey.

As President of Campbell Alliance, Darius Naigamwalla brings extensive pharmaceutical and biotechnology industry expertise to inVentiv Health. Prior to joining Campbell Alliance, Mr. Naigamwalla was a research associate at the University of Western Ontario. He began his career at Campbell Alliance as a consultant in 2001 and has held roles of increasing responsibility since then, moving up the consulting ranks to become a Practice Leader, Managing Director and, most recently, President.

Mr. Naigamwalla holds an MBA from the University of Victoria, a master’s degree in biochemistry and molecular biology from the University of Western Ontario, and a bachelor’s degree in biochemistry from McMaster University.